In vitro activities of pazufloxacin, an injectable new quinolone, against bacteria causing infections in obstetric and gynecological patients

• Published in: Japanese Journal of Chemotherapy Vol. 47; no. Supplement1; pp. 21 - 24
• Main Authors: Hayasaki, Yoh, Sato, Yasumasa, Tamaya, Teruhiko, Kawazoe, Kyoko, Izumi, Koji, Mikamo, Hiroshige, Yamada, Yoshitaka, Ito, Kunihiko
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1999; 公益社団法人 日本化学療法学会
• Subjects: pazufloxacin; 抗菌力; 産婦人科感染症原因菌
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.47.Supplement1_21

Pazufloxacin is an injectable new quinolone with a broad spectrum of antibacterial activity. The MICs of pazufloxacin for 50% of the clinical isolates tested were 3.13μg/ml for Streptococcus agalactiae, 6.25μg/ml for Gardnerella vaginalis, 0.025μg/ml for Escherichiu coli, 0.78μg/ml for Pseudomonas aeruginosa, 6.25μg/ml for Peptostreptococcus magnus, 6.25μg ml for Bucteroides fragilis and 12.5 μg/ml for Prevotella bivia. The MICs of pazufloxacin for 90 % of the clinical isolates tested were 3.13 μg/ml for S. agalactiae, 6.25 μg/ml for G. vaginalis, 0.10 μg/ml for E. coli, 12.5 μg/ml for P. aeruginosa, 25 μg/ml for P. magnus, 12.5 fig/ml for B. fragilis and 25 μg/ml for P. hivia. The results of this study suggest that, subject to confirmation by clinical trials, pazufloxacin, in combination with an agent with reliable activity against anaerobic bacteria, issuitable as empirical therapy of patients with obstetric and gynecological infections.